HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

triscarbonyl(histidinato)molybdate(III)

a carbon monoxide-releasing molecule; structure in first source

Also Known As:

(Mo(CO)3(histidinato)); ALF-186

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Coordination Complexes: 576
  - triscarbonyl(histidinato)molybdate(III): 2
Organic Chemicals: 133
- Coordination Complexes: 576
  - triscarbonyl(histidinato)molybdate(III): 2

Experts

1.	Biermann, Julia: 2 articles (01/2017 - 01/2016)
2.	Buerkle, Hartmut: 2 articles (01/2017 - 01/2016)
3.	Goebel, Ulrich: 2 articles (01/2017 - 01/2016)
4.	Ulbrich, Felix: 2 articles (01/2017 - 01/2016)
5.	Hagmann, Claus: 1 article (01/2017)
6.	Romao, Carlos C: 1 article (01/2017)
7.	Schallner, Nils: 1 article (01/2017)
8.	Augustynik, Michael: 1 article (01/2016)
9.	Kaufmann, Kai B: 1 article (01/2016)
10.	Lagrèze, Wolf A: 1 article (01/2016)

Related Diseases

1.	Reperfusion Injury 01/01/2016 - "The CORM ALF-186 Mediates Anti-Apoptotic Signaling via an Activation of the p38 MAPK after Ischemia and Reperfusion Injury in Retinal Ganglion Cells." 01/01/2016 - "We hypothesize that the carbon monoxide releasing molecule (CORM) ALF-186, administered after neuronal ischemia-reperfusion injury (IRI), counteracts retinal apoptosis and its involved signaling pathways and consecutively reduces neuronal tissue damage. " 01/01/2017 - "The Carbon monoxide releasing molecule ALF-186 mediates anti-inflammatory and neuroprotective effects via the soluble guanylate cyclase ß1 in rats' retinal ganglion cells after ischemia and reperfusion injury."
2.	Ischemia 01/01/2017 - "Ischemia-reperfusion mediated loss of vital RGC was attenuated by the administration of ALF-186 after injury. " 01/01/2016 - "The CORM ALF-186 Mediates Anti-Apoptotic Signaling via an Activation of the p38 MAPK after Ischemia and Reperfusion Injury in Retinal Ganglion Cells." 01/01/2017 - "The Carbon monoxide releasing molecule ALF-186 mediates anti-inflammatory and neuroprotective effects via the soluble guanylate cyclase ß1 in rats' retinal ganglion cells after ischemia and reperfusion injury."
3.	Ganglion Cysts (Ganglion) 01/01/2017 - "The sGC-inhibitor ODQ attenuated the anti-inflammatory effects of ALF-186 and increased retinal loss of ganglion cells. "
4.	Inflammation (Inflammations) 01/01/2017 - "ALF-186 may present a promising therapeutic alternative in treating inflammation after neuronal IRI." 01/01/2017 - "In this investigation, we aimed to analyze the effects of the CORM ALF-186 on neuro-inflammation and hypothesized that the soluble guanylate cyclase (sGC) is playing a decisive role. "
5.	Neuroinflammatory Diseases 01/01/2017 - "Furthermore, ALF-186 reduced IRI mediated neuroinflammation in the retina and in the serum by activating sGC. "

Related Drugs and Biologics

1.	Retinaldehyde (Retinal)
2.	Carbon Monoxide
3.	p38 Mitogen-Activated Protein Kinases
4.	Neuroprotective Agents
5.	Soluble Guanylyl Cyclase